195 related articles for article (PubMed ID: 21209794)
21. Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines.
Choun K; Pe R; Thai S; Lorent N; Lynen L; van Griensven J
Bull World Health Organ; 2013 Mar; 91(3):195-206. PubMed ID: 23476092
[TBL] [Abstract][Full Text] [Related]
22. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti.
Koenig SP; Bang H; Severe P; Jean Juste MA; Ambroise A; Edwards A; Hippolyte J; Fitzgerald DW; McGreevy J; Riviere C; Marcelin S; Secours R; Johnson WD; Pape JW; Schackman BR
PLoS Med; 2011 Sep; 8(9):e1001095. PubMed ID: 21949643
[TBL] [Abstract][Full Text] [Related]
24. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.
Johnson LF; Mossong J; Dorrington RE; Schomaker M; Hoffmann CJ; Keiser O; Fox MP; Wood R; Prozesky H; Giddy J; Garone DB; Cornell M; Egger M; Boulle A;
PLoS Med; 2013; 10(4):e1001418. PubMed ID: 23585736
[TBL] [Abstract][Full Text] [Related]
25. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
Lorenzana SB; Hughes MD; Grinsztejn B; Collier AC; Luz PM; Freedberg KA; Wood R; Levison JH; Mugyenyi PN; Salata R; Wallis CL; Weinstein MC; Schooley RT; Walensky RP
AIDS; 2012 Jun; 26(9):1083-93. PubMed ID: 22343964
[TBL] [Abstract][Full Text] [Related]
26. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?
Beck EJ; Vitoria M; Mandalia S; Crowley S; Gilks CF; Souteyrand Y
AIDS; 2006 Jul; 20(11):1497-502. PubMed ID: 16847404
[TBL] [Abstract][Full Text] [Related]
27. Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs.
Ndakala FN; Oyugi JO; Oluka MN; Kimani J; Jablonka A; Behrens GM
Pan Afr Med J; 2016; 25():14. PubMed ID: 28154706
[TBL] [Abstract][Full Text] [Related]
28. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.
Stringer JS; Zulu I; Levy J; Stringer EM; Mwango A; Chi BH; Mtonga V; Reid S; Cantrell RA; Bulterys M; Saag MS; Marlink RG; Mwinga A; Ellerbrock TV; Sinkala M
JAMA; 2006 Aug; 296(7):782-93. PubMed ID: 16905784
[TBL] [Abstract][Full Text] [Related]
29. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?
Brennan AT; Davies MA; Bor J; Wandeler G; Stinson K; Wood R; Prozesky H; Tanser F; Fatti G; Boulle A; Sikazwe I; Wool-Kaloustian K; Yuannoutsos C; Leroy V; de Rekeneire N; Fox MP
AIDS; 2017 Jan; 31(1):147-157. PubMed ID: 27776039
[TBL] [Abstract][Full Text] [Related]
30. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Forna F; Liechty CA; Solberg P; Asiimwe F; Were W; Mermin J; Behumbiize P; Tong T; Brooks JT; Weidle PJ
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):456-62. PubMed ID: 17279048
[TBL] [Abstract][Full Text] [Related]
31. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
Chang LW; Harris J; Humphreys E
Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
[TBL] [Abstract][Full Text] [Related]
32. HIV treatment and care in resource-constrained environments: challenges for the next decade.
Eholié SP; Aoussi FE; Ouattara IS; Bissagnéné E; Anglaret X
J Int AIDS Soc; 2012 Aug; 15(2):17334. PubMed ID: 22944479
[TBL] [Abstract][Full Text] [Related]
33. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
Holmes CB; Zheng H; Martinson NA; Freedberg KA; Walensky RP
Clin Infect Dis; 2006 Jun; 42(12):1772-80. PubMed ID: 16705586
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
[TBL] [Abstract][Full Text] [Related]
35. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
Ciaranello AL; Lockman S; Freedberg KA; Hughes M; Chu J; Currier J; Wood R; Holmes CB; Pillay S; Conradie F; McIntyre J; Losina E; Walensky RP;
AIDS; 2011 Feb; 25(4):479-92. PubMed ID: 21293199
[TBL] [Abstract][Full Text] [Related]
36. Uptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia.
Duber HC; Dansereau E; Masters SH; Achan J; Burstein R; DeCenso B; Gasasira A; Ikilezi G; Kisia C; Masiye F; Njuguna P; Odeny T; Okiro E; Roberts DA; Gakidou E
PLoS One; 2015; 10(3):e0120350. PubMed ID: 25807553
[TBL] [Abstract][Full Text] [Related]
37. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.
Sax PE; Sloan CE; Schackman BR; Grant PM; Rong J; Zolopa AR; Powderly W; Losina E; Freedberg KA;
HIV Clin Trials; 2010; 11(5):248-59. PubMed ID: 21126955
[TBL] [Abstract][Full Text] [Related]
38. The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.
Ross E; Tanser F; Pei P; Newell ML; Losina E; Thiebaut R; Weinstein M; Freedberg K; Anglaret X; Scott C; Dabis F; Walensky R
HIV Clin Trials; 2014; 15(5):185-98. PubMed ID: 25350957
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.
Losina E; Touré H; Uhler LM; Anglaret X; Paltiel AD; Balestre E; Walensky RP; Messou E; Weinstein MC; Dabis F; Freedberg KA; ;
PLoS Med; 2009 Oct; 6(10):e1000173. PubMed ID: 19859538
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
